The company’s latest flow chemistry investment strengthens continuous processing offering for clinical and commercial manufacturing programs

Almac Sciences, a member of the Almac Group, is pleased to announce a significant expansion of its API and flow chemistry services with the launch of cGMP compliant flow high pressure hydrogenation. This new capability brings enhanced precision, safety, and scalability to one of the most critical transformations in modern synthetic chemistry and is now available for both clinical and commercial manufacturing programs.

Hydrogenation is an essential step across many synthetic routes and performing it under continuous flow conditions offers transformative benefits. Flow operation provides superior control over temperature, pressure, and mixing, enabling improved reaction performance, reduced impurity formation, and reliable reproducibility at scale. By integrating this technology under cGMP conditions, Almac Sciences now gives clients access to faster, safer, and more efficient hydrogenation up to 100 bar pressure and 300 deg C with the confidence of full regulatory compliance and rigorous analytical oversight.

This advancement builds on over eight years of substantial investment in flow chemistry, during which Almac Sciences has developed deep expertise in packed-bed hydrogenation and demonstrated robust performance at scales exceeding 100 kg. The addition of cGMP capability further strengthens Almac’s position as a leading provider of manufacturing solutions.

“This investment marks a significant milestone for our team and our clients,” said Dr. Scott Wharry, Associate Director of Custom and Flow Chemistry at Almac Sciences. “By combining cGMP flow hydrogenation with our established expertise in cryogenic organometallic chemistry and large scale packed-bed hydrogenation, we are offering continuous processing capability today. These technologies not only improve safety and efficiency but also align with the industry’s drive toward sustainability and innovation.”

With this latest investment, Almac Sciences continues to expand its comprehensive continuous flow offering, providing global partners with cutting-edge technologies backed by the company’s multidisciplinary team of chemists, engineers, analysts, automation specialists, and project managers. This integrated expertise ensures clients receive not only technical excellence but also strategic guidance and support at every stage of their molecule’s journey.

Prof. Tom Moody, VP API Development and Commercialisation, added: “Flow hydrogenation under cGMP is a major step forward for our customers. It delivers enhanced process confidence, consistent high quality output, and exceptional scalability, all while reducing environmental impact and operational risk. As the industry increasingly prioritises safer, greener, and more flexible manufacturing solutions, this capability reinforces our commitment to supporting clients from early development right through to commercialisation.”